002932 Wuhan Easy Diagnosis BiomedicineWatchlist
About Wuhan Easy Diagnosis Biomedicine Company
The company was founded in 2008 and specializes in providing in vitro diagnostic reagents and supporting instrument products and integrated emergency and critical illness treatment. Currently, the company's main business has covered nearly 5,000 medical institutions in 30 provinces, municipalities directly under the Central Government and autonomous regions across the country, while also achieving a sales layout in various regions such as Asia, the European Union, and South America. In the fight against the COVID-19 epidemic, Mingde Biotech urgently developed a COVID-19 nucleic acid test kit and obtained a registration certificate, becoming a representative IVD enterprise in the affected area. At the same time, Mingde's COVID-19 nucleic acid reagents, antibody detection reagents, and blood gas analyzers have also obtained CE approval from the European Union and are eligible to be sold abroad. The company is mainly engaged in R&D, production, sales and service of in vitro diagnostic reagents and diagnostic instruments, and is committed to becoming a leading enterprise providing innovative and leading medical service products to medical institutions. The company's main products and services cover three areas: in vitro diagnostic reagents and instruments, emergency and critical illness informatization solutions, and third-party medical testing services. In addition, the company has other businesses such as selling a small number of proxy products and selling mobile square cabin PCR laboratories. Corporate honors: China's top 100 influential pharmaceutical companies, the top ten POCT brands recognized by the inspectors, etc., the outstanding enterprises in innovation and development in 2017, and the second batch of invisible champions in key industrial segments in Hubei Province.
Matilda Biotech (002932.SZ): 1,940,400 restricted stocks will be unbanned on October 9
Glonghui, September 26丨Mingde Biotech (002932.SZ) announced an indicative announcement on the 2019 Restricted Stock Incentive Plan for the first time, the third unlocking period for restricted stocks, the third unlocking period to lift the sale restrictions, and the listing and circulation of restricted shares. The number of restricted shares lifted this time was 1,904,414 million shares, accounting for about 0.8345% of the company's current total share capital of 232,520,957 shares. The number of people applying for the lifting of sales restrictions is 52. The listing and circulation date of the lifted shares is October 9, 2023 (Monday).
Matilda Biotech (002932.SZ): Net profit for the first half of the year fell 95.92% to 113 million yuan
GLONGHUI, August 30 | Mingde Biotech (002932.SZ) announced its 2023 semi-annual report. Operating income for the reporting period was 538 million yuan, down 89.77% year on year; net profit attributable to shareholders of listed companies was 113 million yuan, down 95.92% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 35.031 million yuan, down 98.73% year on year; basic earnings per share were 0.49 yuan.
Matilda Biotech (002932.SZ): Regular business development in the third quarter was good, and orders were stable
GLONGHUI, August 28丨Some investors asked Mingde Biotech (002932.SZ), “How was the company's regular business in the third quarter? Is the order stable?” Mingde Biotech replied that the company's regular business development in the third quarter was good and orders were stable!